This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Avocent, CenterPoint Energy: Ratings Changes

TheStreet.com Ratings provides exclusive stock, ETF and mutual fund ratings and commentary based on award-winning, proprietary tools. Its "safety first" approach to investing aims to reduce risk while seeking total return performance.

BOSTON ( TheStreet) -- TheStreet.com's stock-rating model upgraded communications equipment maker Avocent (AVCT) to "hold."

The numbers: The company swung to a second-quarter loss of $3.4 million, or 8 cents a share, from a profit of $3.4 million, or 8 cents, in the year-earlier period. Revenue declined 19% to $129 million. Its gross margin remained steady at 59%, but its operating margin fell from 7% to 2%. A quick ratio of 1.4 demonstrates ample liquidity. A debt-to-equity ratio of 0.2 indicates modest leverage.

The stock: Avocent has advanced 18% this year, outpacing the Dow Jones Industrial Average and S&P 500 Index. The company, which posted losses for the past two quarters, doesn't pay dividends.

The model downgraded utility CenterPoint Energy (CNP - Get Report) to "hold."

The numbers: Second-quarter net income dropped 15% to $86 million, or 24 cents a share. Revenue declined 39% to $1.6 billion. Its gross margin rose from 18% to 27% and its operating margin increased from 11% to 15%. A quick ratio of 0.5 indicates less-than-ideal liquidity. A debt-to-equity ratio of 4.5 demonstrates excessive leverage.

The stock: CenterPoint has fallen 1% this year, trailing major U.S. indices. The stock trades at a price-to-earnings ratio of 12, a discount to the market and utility peers. The shares offer a 6.1% dividend yield.

The model downgraded insurer Donegal Group (DGICA - Get Report) to "hold."

The numbers: Second-quarter revenue grew 1% to $95 million, but profit dropped 31% to $4.4 million, or 17 cents a share. Its gross margin fell from 10% to 6% and its operating margin decreased from 9% to 6%. The company has an ideal financial position, with $69 million of cash and $15 million of debt.

The stock: Donegal Group is down 7% this year, lagging behind major U.S. indices. The stock trades at a price-to-earnings ratio of 23, a premium to the market, but a discount to other insurers. The shares offer a 2.9% dividend yield.

The model upgraded China-based medical device maker Mindray Medical International (MR - Get Report) to "buy."

The numbers: Second-quarter profit increased 37% to $33 million, or 29 cents a share, as revenue jumped 10% to $160 million. Its gross margin rose from 53% to 57%, but its operating margin remained steady at 24%. A quick ratio of 1.4 indicates adequate liquidity. A debt-to-equity ratio of 0.3 demonstrates conservative leverage.

The stock: Mindray Medical has surged 81% this year, beating major U.S. indices. The stock trades at a price-to-earnings ratio of 31, a premium to the market, but a discount to medical equipment peers. The shares offer a 0.6% dividend yield.

The model downgraded oil and gas trust San Juan Basin Royalty Trust (SJT - Get Report) to "hold."

The numbers: Second-quarter profit plummeted 95% to $1.8 million, or 4 cents a share, as revenue fell 93% to $2.5 million. Its gross margin was little-changed at 100%, but its operating margin fell from 98% to 72%. The company has a strong financial position, with $430,000 of cash and no debt.

The stock: San Juan Basin Royalty Trust is down 42% this year, lagging behind major U.S. indices. The stock trades at a price-to-earnings ratio of 9, a discount to the market and oil and gas peers. The shares offer a 3.6% dividend yield.

-- Reported by Jake Lynch in Boston.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
CNP $20.27 0.00%
DGICA $14.38 0.00%
MR $26.96 0.00%
SJT $10.95 0.00%
AAPL $129.62 0.00%

Markets

DOW 18,041.54 -190.48 -1.04%
S&P 500 2,104.20 -21.86 -1.03%
NASDAQ 5,032.7510 -56.6110 -1.11%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs